In future studies, clinical sample staining will be evaluated to assess the diagnostic accuracy of the DDSI methodology in mixed, heterogeneous samples, and additional biomarkers will be evaluated for low PSMA expressing prostate cancers. This evidence concerns the gene FOLH1 and prostate carcinoma.